MyocardON-TTR - Myocardial Effects in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy Treated with Patisiran or Vutrisiran
ATTRv amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms). Patisiran and vutrisiran have shown protective effects on the progression of neurological damage. The effects of Patisiran or vutrisiran on the heart remain incompletely understood. The aim of this study is to better understand the morphological and functional cardiac consequences in ATTRv patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran or vutrisiran
• Patients aged 18 years or older
• Patients with hereditary transthyretin amyloidosis (ATTRv) with stage 1 or 2 polyneuropathy
• Patient not previously treated for ATTRv
• Patients for whom treatment with patisiran or vutrisiran has been initiated by a hospital neurologist in accordance with recommendations for a minimum of 24 months.
• Patients with NYHA stage 1 and 2 cardiac disease.
• Beneficiary of a social security scheme
• Person who does not object to his/her participation in the research